Bioventix Plc Issue of Equity

 
TIDMBVXP 
 
Bioventix plc 
                        ("Bioventix" or the "Company") 
 
                                Issue of Equity 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, announces that it has applied for 1,498 ordinary shares 
of 5 pence each (the "Option Shares") to be admitted to trading on AIM 
("Admission"). It is expected that Admission will occur and that dealings will 
commence in the Option Shares on 13 July 2020. 
 
The Option Shares are being issued pursuant to an exercise of options by an 
employee of the Company. The Option Shares will rank pari passu with the 
existing Ordinary Shares. 
 
The total number of Ordinary Shares in issue following Admission will be 
5,209,333 and the Company holds no shares in treasury. Therefore, the total 
number of Ordinary Shares with voting rights in the Company will be 5,209,333. 
 
The above figure of 5,209,333 may be used by shareholders as the denominator 
for the calculations by which they will determine if they are required to 
notify their interest in, or a change to their interest in, Bioventix under the 
FCA's Disclosure Guidance and Transparency Rules. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: [phone] 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: [phone] 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END 
 

(END) Dow Jones Newswires

July 08, 2020 02:00 ET (06:00 GMT)